Physician profile
Thomas Chwe
NPI 1144533936
$2,112.08
in general payments reported to CMS, 2019-2025
15 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.23 · 2020: $241 · 2021: $193 · 2022: $241 · 2023: $340 · 2024: $594 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $451.92 | 2023-2025 | |
| Alcon Vision LLC | $379.97 | 2020-2024 | Precision 1, Rocklatan, Argos |
| Abbvie INC. | $348.43 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $159.85 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $133.13 | 2022-2025 | Vyzulta, Infuse, Xiidra |
| Tarsus Pharmaceuticals, INC. | $115.30 | 2024 | Xdemvy |
| Dompe US, INC. | $107.84 | 2025 | Oxervate |
| Coopervision INC. | $88.08 | 2023-2024 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $76.03 | 2021-2023 | Acuvue |
| Aerie Pharmaceuticals, INC. | $69.63 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.28 | 2019-2020 | |
| Omeros Corporation | $51.96 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $26.81 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.67 | 2021 | |
| Sight Sciences, INC. | $17.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.